Caitlin S. Brown, Fi Fonseca, Kyle A. Schofield, Kharmene Sunga, Tiffany Olswold, Justine Herndon, Keith Roe, Caroline Davidge-Pitts, Kellyn Engstrom
Transgender and gender diverse (TGD) individuals face minority stress and often avoid the emergency department (ED) due to previous negative experiences. The goal of this review is to prepare the emergency medicine pharmacist to care for TGD patients, with the ultimate goal of improving the care TGD patients receive. This review summarizes interactions with TGD patients, trauma-informed considerations, physical exam and organ inventory sensitivities, and gender-affirming hormone therapy and complications that may arise and be seen in the ED. Additionally, this review discusses common complaints and considerations that may commonly arise when caring for TGD patients.
{"title":"Enhancing Care: Caring for Transgender and Gender Diverse Patients in the Emergency Department","authors":"Caitlin S. Brown, Fi Fonseca, Kyle A. Schofield, Kharmene Sunga, Tiffany Olswold, Justine Herndon, Keith Roe, Caroline Davidge-Pitts, Kellyn Engstrom","doi":"10.1002/jac5.70122","DOIUrl":"https://doi.org/10.1002/jac5.70122","url":null,"abstract":"<div>\u0000 \u0000 <p>Transgender and gender diverse (TGD) individuals face minority stress and often avoid the emergency department (ED) due to previous negative experiences. The goal of this review is to prepare the emergency medicine pharmacist to care for TGD patients, with the ultimate goal of improving the care TGD patients receive. This review summarizes interactions with TGD patients, trauma-informed considerations, physical exam and organ inventory sensitivities, and gender-affirming hormone therapy and complications that may arise and be seen in the ED. Additionally, this review discusses common complaints and considerations that may commonly arise when caring for TGD patients.</p>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 11","pages":"1175-1186"},"PeriodicalIF":1.5,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145493670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elizabeth K. Tripp, Susan J. Lewis, Jennifer L. Richardson
Introduction
Diabetes distress (DD) is an emotional response to the demands of diabetes mellitus (DM) management and is associated with poor glycemic control, reduced self-care, and lower quality of life. Despite its significance, DD remains under-recognized in hospitalized patients where acute illness may intensify the emotional burden. Hospitalization offers an opportunity for identification, but routine practices are lacking. This study assessed the prevalence and predictors of DD using a pharmacist-led screening approach among hospitalized adults with DM.
Methods
This prospective, single-center, quality improvement initiative was conducted at a small community hospital. Pharmacists and trained pharmacy students administered the validated 17-item Diabetes Distress Scale (DDS) to eligible inpatients with DM. A mean DDS score ≥ 2.0 indicated moderate-to-high DD. The primary outcome was the prevalence of moderate-to-high DD; secondary outcomes included contributing domains and associated patient characteristics. Descriptive statistics and logistic regression were performed using SAS v9.4 (p < 0.05).
Results
Of 301 patients surveyed, 103 (34%) reported moderate-to-high DD. The median overall score with an interquartile range (IQR) was 2.71 (2.29–3.41) in the moderate-to-high DD group, compared with 1.26 (IQR 1.06–1.53) in the none-to-low group. Emotional burden and regimen distress were the most common contributing domains. Independent predictors of moderate-to-high DD included a hemoglobin A1c (HbA1c) ≥ 9%, a history of depression, number of insulin injections daily, diabetic retinopathy, and any diabetes-related complications. Prior DD screening was reported by 12%. Of 126 patients requesting support, 78% received a referral to the outpatient diabetes clinic.
Conclusion
Pharmacist-led screening identified one-third of hospitalized DM patients who were experiencing moderate-to-high DD, and most were never previously assessed. While routine hospital-based screening for DD is not a standard practice, implementing such screening could enhance DM care.
{"title":"Prevalence and Predictors of Diabetes Distress in Hospitalized Patients: A Pharmacist-Led Intervention","authors":"Elizabeth K. Tripp, Susan J. Lewis, Jennifer L. Richardson","doi":"10.1002/jac5.70121","DOIUrl":"https://doi.org/10.1002/jac5.70121","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Diabetes distress (DD) is an emotional response to the demands of diabetes mellitus (DM) management and is associated with poor glycemic control, reduced self-care, and lower quality of life. Despite its significance, DD remains under-recognized in hospitalized patients where acute illness may intensify the emotional burden. Hospitalization offers an opportunity for identification, but routine practices are lacking. This study assessed the prevalence and predictors of DD using a pharmacist-led screening approach among hospitalized adults with DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective, single-center, quality improvement initiative was conducted at a small community hospital. Pharmacists and trained pharmacy students administered the validated 17-item Diabetes Distress Scale (DDS) to eligible inpatients with DM. A mean DDS score ≥ 2.0 indicated moderate-to-high DD. The primary outcome was the prevalence of moderate-to-high DD; secondary outcomes included contributing domains and associated patient characteristics. Descriptive statistics and logistic regression were performed using SAS v9.4 (<i>p</i> < 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 301 patients surveyed, 103 (34%) reported moderate-to-high DD. The median overall score with an interquartile range (IQR) was 2.71 (2.29–3.41) in the moderate-to-high DD group, compared with 1.26 (IQR 1.06–1.53) in the none-to-low group. Emotional burden and regimen distress were the most common contributing domains. Independent predictors of moderate-to-high DD included a hemoglobin A1c (HbA1c) ≥ 9%, a history of depression, number of insulin injections daily, diabetic retinopathy, and any diabetes-related complications. Prior DD screening was reported by 12%. Of 126 patients requesting support, 78% received a referral to the outpatient diabetes clinic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pharmacist-led screening identified one-third of hospitalized DM patients who were experiencing moderate-to-high DD, and most were never previously assessed. While routine hospital-based screening for DD is not a standard practice, implementing such screening could enhance DM care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 11","pages":"1153-1160"},"PeriodicalIF":1.5,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145493745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caitlin M. Gordon, Billy Yu, Frank Leung, Michael Legal, Janet Simons, Erica Wang, Michelle Gnyra
Introduction
Biased language in documentation can perpetuate stigma, influence treatment decisions, and impact provider–patient relationships. As any person seeking care at acute care hospitals may face stigma, particularly those with substance use or mental health disorders, unbiased documentation is crucial. We sought to determine the prevalence of stigmatizing and biased language in electronic health records written by clinical pharmacists.
Methods
This study was conducted at two acute care teaching hospitals, St. Paul's and Mount Saint Joseph Hospitals in Vancouver, British Columbia, Canada. A list of stigmatizing and biased terms was compiled through literature review and expert consensus. A retrospective, observational, cross-sectional study of clinical pharmacist notes was performed using a data-mining algorithm to identify these terms. A content analysis was conducted to explore the ways this terminology was used and to uncover new themes not previously documented in the literature.
Results
Between November 16, 2019, and September 30, 2023, of 135 671 clinical pharmacist notes reviewed, 42 192 (31.1%) contained at least one stigmatizing or biased term. Commonly identified terms included: compliance, noncompliance, refuses, denies, and smoker. All themes previously documented in the literature (e.g., leading with race/socioeconomic status, incorrect pronouns, employing quotations to suggest lack of credibility) were observed. Additionally, new themes emerged, including the use of punctuation or formatting to amplify the stigmatizing tone and the role of electronic health records in perpetuating stigma.
Discussion
Stigmatizing language was found in 31.1% of clinical pharmacist notes. Findings from this study are assisting in the development of a multimodal educational intervention aimed at reducing the prevalence of stigmatizing language in clinical pharmacist documentation.
{"title":"Characterizing Stigmatizing and Biased Language in Clinical Pharmacist Documentation","authors":"Caitlin M. Gordon, Billy Yu, Frank Leung, Michael Legal, Janet Simons, Erica Wang, Michelle Gnyra","doi":"10.1002/jac5.70119","DOIUrl":"https://doi.org/10.1002/jac5.70119","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Biased language in documentation can perpetuate stigma, influence treatment decisions, and impact provider–patient relationships. As any person seeking care at acute care hospitals may face stigma, particularly those with substance use or mental health disorders, unbiased documentation is crucial. We sought to determine the prevalence of stigmatizing and biased language in electronic health records written by clinical pharmacists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study was conducted at two acute care teaching hospitals, St. Paul's and Mount Saint Joseph Hospitals in Vancouver, British Columbia, Canada. A list of stigmatizing and biased terms was compiled through literature review and expert consensus. A retrospective, observational, cross-sectional study of clinical pharmacist notes was performed using a data-mining algorithm to identify these terms. A content analysis was conducted to explore the ways this terminology was used and to uncover new themes not previously documented in the literature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between November 16, 2019, and September 30, 2023, of 135 671 clinical pharmacist notes reviewed, 42 192 (31.1%) contained at least one stigmatizing or biased term. Commonly identified terms included: compliance, noncompliance, refuses, denies, and smoker. All themes previously documented in the literature (e.g., leading with race/socioeconomic status, incorrect pronouns, employing quotations to suggest lack of credibility) were observed. Additionally, new themes emerged, including the use of punctuation or formatting to amplify the stigmatizing tone and the role of electronic health records in perpetuating stigma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Stigmatizing language was found in 31.1% of clinical pharmacist notes. Findings from this study are assisting in the development of a multimodal educational intervention aimed at reducing the prevalence of stigmatizing language in clinical pharmacist documentation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 10","pages":"974-982"},"PeriodicalIF":1.5,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.70119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145248508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Steven R. Erickson, Ariana Nigoghosian, Brianna Marzolf, Beatrice Palazzolo, Dawn Michael, Muhammad Othman, Michael M. McKee
Introduction
People with intellectual or developmental disabilities face an elevated risk of adverse medication and health outcomes due to polypharmacy, medication interactions, and adherence issues. This study's objective was to assess the feasibility of virtual and in-home comprehensive medication reviews (CMRs) to identify and, when necessary, intervene on medication-related problems (MRPs) among patients with intellectual or developmental disabilities (IDD) residing in community group homes and to assess the caregivers' satisfaction with the CMRs.
Methods
Patients with IDD taking 5 or more medications were detected by using the health system's data warehouse. CMR steps included meeting with the patient and caregiver, assessing for MRP using the American Pharmacist Association/National Association of Chain Drug Stores framework, and providing a summary report for the patient/caregiver/prescriber. The report was reviewed with the caregiver 2 weeks after the initial CMR visit and sent to the prescriber. Outcomes measured included changes in the number of medications in patients' regimens, the number of MRPs identified, and a description of the MRPs.
Results
Twenty-nine patients with IDD received the CMR intervention. A median and interquartile range (IQR) of 4 (3.0, 4.0) MRPs were identified for each patient. The most common MRPs were inaccurate medication list in the medical record (n = 21), duplication of therapy (n = 13), no indication for medication use documented (n = 8), and a potential problem present but not treated (n = 7). There was a statistically significant difference in the median number of medications prior to and after CMR (p = 0.046), which decreased from 16 (12, 19) to 14.5 (10.8, 18.3). Caregivers were highly satisfied with the CMR process.
Conclusion
These results support the feasibility of conducting CMR both virtually and in-home. Implementation of a CMR program on a larger scale and conducting outcomes assessment are the next steps, with the goal to ensure safe and effective use of their medications by patients who have IDD.
{"title":"Comprehensive Medication Reviews for Adults With Intellectual or Developmental Disabilities","authors":"Steven R. Erickson, Ariana Nigoghosian, Brianna Marzolf, Beatrice Palazzolo, Dawn Michael, Muhammad Othman, Michael M. McKee","doi":"10.1002/jac5.70120","DOIUrl":"https://doi.org/10.1002/jac5.70120","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>People with intellectual or developmental disabilities face an elevated risk of adverse medication and health outcomes due to polypharmacy, medication interactions, and adherence issues. This study's objective was to assess the feasibility of virtual and in-home comprehensive medication reviews (CMRs) to identify and, when necessary, intervene on medication-related problems (MRPs) among patients with intellectual or developmental disabilities (IDD) residing in community group homes and to assess the caregivers' satisfaction with the CMRs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with IDD taking 5 or more medications were detected by using the health system's data warehouse. CMR steps included meeting with the patient and caregiver, assessing for MRP using the American Pharmacist Association/National Association of Chain Drug Stores framework, and providing a summary report for the patient/caregiver/prescriber. The report was reviewed with the caregiver 2 weeks after the initial CMR visit and sent to the prescriber. Outcomes measured included changes in the number of medications in patients' regimens, the number of MRPs identified, and a description of the MRPs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-nine patients with IDD received the CMR intervention. A median and interquartile range (IQR) of 4 (3.0, 4.0) MRPs were identified for each patient. The most common MRPs were inaccurate medication list in the medical record (<i>n</i> = 21), duplication of therapy (<i>n</i> = 13), no indication for medication use documented (<i>n</i> = 8), and a potential problem present but not treated (<i>n</i> = 7). There was a statistically significant difference in the median number of medications prior to and after CMR (<i>p</i> = 0.046), which decreased from 16 (12, 19) to 14.5 (10.8, 18.3). Caregivers were highly satisfied with the CMR process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These results support the feasibility of conducting CMR both virtually and in-home. Implementation of a CMR program on a larger scale and conducting outcomes assessment are the next steps, with the goal to ensure safe and effective use of their medications by patients who have IDD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 11","pages":"1161-1166"},"PeriodicalIF":1.5,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.70120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145493713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The emerging capabilities of large language models (LLMs) have drawn increasing attention across various fields, including pharmacy practice in Thailand. Given the extensive number of available medications and the complex, often perplexing prescribing patterns, medication review remains a critical responsibility for pharmacists. This study explored the potential role of LLMs in supporting the medication review process within the Thai health care context, specifically focusing on their ability to detect drug interactions (DIs) and suggest context-sensitive management strategies.
Methods
Ten clinical vignettes were constructed, each depicting a patient with a specific drug regimen seeking assistance from a pharmacist. These cases were tailored to reflect the Thai context and represent commonly encountered DIs in Thailand. Each vignette was submitted to a set of LLMs—ChatGPT-4, ChatGPT-4o, ChatGPT-4o mini, Gemini 1.5, Claude 3.5, Microsoft Copilot, and Alisa 3.0—in both English and Thai. Evaluation metrics were developed and validated using the Index of Item-Objective Congruence. Two independent evaluators assessed all responses, and inter-rater reliability was measured using weighted Cohen's κ. LLM performance was scored based on percentage ranges, and cumulative scores were reported across evaluation domains.
Results
The weighted Cohen's κ values across six domains—(A) ability to identify DIs, (B) completeness, (C) clarity, (D) citation reliability, (E) usefulness, and (F) ability to assess harm—exceeded 0.6, indicating substantial inter-rater agreement. All LLMs showed clinically acceptable performance in both languages. Citation reliability was limited in Alisa 3.0 and Gemini 1.5, while ChatGPT-4o demonstrated the most consistent and well-rounded performance.
Conclusion
The selected LLMs demonstrated their potential as capable digital assistants in medication reviews, although some models require further improvement and careful consideration when applied in real-world settings. Nevertheless, human oversight remains essential; when used in parallel, LLMs and health professionals can work synergistically to enhance patient outcomes.
{"title":"Capabilities of Large Language Models in Detecting and Managing Drug Interactions During Medication Reviews: Potential Implications as A Digital Assistant for Pragmatic Pharmacy Practice in Thailand","authors":"Nuntapong Boonrit, Achiraya Thaweechai, Bussabong Kessarin, Warit Ruanglertboon","doi":"10.1002/jac5.70115","DOIUrl":"https://doi.org/10.1002/jac5.70115","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The emerging capabilities of large language models (LLMs) have drawn increasing attention across various fields, including pharmacy practice in Thailand. Given the extensive number of available medications and the complex, often perplexing prescribing patterns, medication review remains a critical responsibility for pharmacists. This study explored the potential role of LLMs in supporting the medication review process within the Thai health care context, specifically focusing on their ability to detect drug interactions (DIs) and suggest context-sensitive management strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Ten clinical vignettes were constructed, each depicting a patient with a specific drug regimen seeking assistance from a pharmacist. These cases were tailored to reflect the Thai context and represent commonly encountered DIs in Thailand. Each vignette was submitted to a set of LLMs—ChatGPT-4, ChatGPT-4o, ChatGPT-4o mini, Gemini 1.5, Claude 3.5, Microsoft Copilot, and Alisa 3.0—in both English and Thai. Evaluation metrics were developed and validated using the Index of Item-Objective Congruence. Two independent evaluators assessed all responses, and inter-rater reliability was measured using weighted Cohen's <i>κ</i>. LLM performance was scored based on percentage ranges, and cumulative scores were reported across evaluation domains.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The weighted Cohen's <i>κ</i> values across six domains—(A) ability to identify DIs, (B) completeness, (C) clarity, (D) citation reliability, (E) usefulness, and (F) ability to assess harm—exceeded 0.6, indicating substantial inter-rater agreement. All LLMs showed clinically acceptable performance in both languages. Citation reliability was limited in Alisa 3.0 and Gemini 1.5, while ChatGPT-4o demonstrated the most consistent and well-rounded performance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The selected LLMs demonstrated their potential as capable digital assistants in medication reviews, although some models require further improvement and careful consideration when applied in real-world settings. Nevertheless, human oversight remains essential; when used in parallel, LLMs and health professionals can work synergistically to enhance patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 11","pages":"1117-1128"},"PeriodicalIF":1.5,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145493691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anne M. Komé, Amanda R. Boykin, Alayah C. Johnson-Jennings, Andrea D. Coviello
Despite soaring demand and prescribing rates, access to anti-obesity medications (AOM) remains unbalanced due to high manufacturer costs, inadequate insurance coverage, intermittent shortages, and lack of provider knowledge in overcoming medication access barriers. Pharmacists are uniquely positioned to bridge care gaps for people with obesity by facilitating medication management, identifying drug interactions, counseling on lifestyle modification and adverse effects, and providing more frequent follow-up. Further, pharmacists can use their expertise to assist with AOM access, affordability, and therapeutic interchange. This article highlights the challenges routinely encountered in chronic weight management while offering practical pearls for pharmacists about insurance coverage, prior authorizations, current affordability initiatives, navigating shortages, and the importance of education and advocacy for people living with obesity.
{"title":"Tipping the Scales: Strategies to Improve Anti-Obesity Medication Access and Affordability","authors":"Anne M. Komé, Amanda R. Boykin, Alayah C. Johnson-Jennings, Andrea D. Coviello","doi":"10.1002/jac5.70118","DOIUrl":"https://doi.org/10.1002/jac5.70118","url":null,"abstract":"<div>\u0000 \u0000 <p>Despite soaring demand and prescribing rates, access to anti-obesity medications (AOM) remains unbalanced due to high manufacturer costs, inadequate insurance coverage, intermittent shortages, and lack of provider knowledge in overcoming medication access barriers. Pharmacists are uniquely positioned to bridge care gaps for people with obesity by facilitating medication management, identifying drug interactions, counseling on lifestyle modification and adverse effects, and providing more frequent follow-up. Further, pharmacists can use their expertise to assist with AOM access, affordability, and therapeutic interchange. This article highlights the challenges routinely encountered in chronic weight management while offering practical pearls for pharmacists about insurance coverage, prior authorizations, current affordability initiatives, navigating shortages, and the importance of education and advocacy for people living with obesity.</p>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 11","pages":"1187-1193"},"PeriodicalIF":1.5,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145493690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on “Consensus Recommendations for the Integration of Critical Care Pharmacists on Intensive Care Unit Teams: Endorsed by the American Association of Critical-Care Nurses, American College of Clinical Pharmacy, American Society of Health-System Pharmacists, Institute for Safe Medication Practices, and Society of Critical Care Medicine”","authors":"John Carr, Dustin Orvin","doi":"10.1002/jac5.70117","DOIUrl":"https://doi.org/10.1002/jac5.70117","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 10","pages":"1101-1102"},"PeriodicalIF":1.5,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145248547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mojdeh S. Heavner, Jason J. Heavner, Brian Murray, Andrea Sikora
{"title":"Response to Comment on “Consensus Recommendations for the Integration of Critical Care Pharmacists on Intensive Care Unit Teams: Endorsed by the American Association of Critical-Care Nurses, American College of Clinical Pharmacy, American Society of Health-System Pharmacists, Institute for Safe Medication Practices, and Society of Critical Care Medicine”","authors":"Mojdeh S. Heavner, Jason J. Heavner, Brian Murray, Andrea Sikora","doi":"10.1002/jac5.70116","DOIUrl":"https://doi.org/10.1002/jac5.70116","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 10","pages":"1103-1104"},"PeriodicalIF":1.5,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145248772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erin Hickey Zacholski, Jack Dierckes, David Hartnett-Quach, Cady Noda, Amanda Sharps, Olivia White, Kyle Zacholski, Shawn P. Griffin
Educating patients and caregivers on anticancer therapy is central to oncology pharmacy practice. As anticancer regimens become more complex, oncology pharmacists need a structured framework that ensures vital information is communicated and personalized to each patient. Though existing organizational guidelines, largely written for nurses, and standards for oral oncolytic therapy counseling provide valuable insight, a dedicated guideline for oncology pharmacists regarding the delivery of patient education for parenteral and combination anticancer therapies is largely bereft. This review addresses that gap, presenting a pharmacist-led model that encompasses the pre-visit assessment, preparation, step-by-step delivery of the teaching session, and practical considerations for maximizing patient understanding and safety.
This narrative review summarizes evidence for effective patient education on parenteral anticancer therapies. The authors propose a structured framework for oncology pharmacist-led patient education on parenteral anticancer therapies that combines pharmacotherapy knowledge and the application of patient-centered care.
{"title":"Comprehensive Framework for Oncology Pharmacist-Led Parenteral Anticancer Therapy Patient Education: The Opinion of the American College of Clinical Pharmacy Hematology/Oncology Practice and Research Network","authors":"Erin Hickey Zacholski, Jack Dierckes, David Hartnett-Quach, Cady Noda, Amanda Sharps, Olivia White, Kyle Zacholski, Shawn P. Griffin","doi":"10.1002/jac5.70114","DOIUrl":"https://doi.org/10.1002/jac5.70114","url":null,"abstract":"<p>Educating patients and caregivers on anticancer therapy is central to oncology pharmacy practice. As anticancer regimens become more complex, oncology pharmacists need a structured framework that ensures vital information is communicated and personalized to each patient. Though existing organizational guidelines, largely written for nurses, and standards for oral oncolytic therapy counseling provide valuable insight, a dedicated guideline for oncology pharmacists regarding the delivery of patient education for parenteral and combination anticancer therapies is largely bereft. This review addresses that gap, presenting a pharmacist-led model that encompasses the pre-visit assessment, preparation, step-by-step delivery of the teaching session, and practical considerations for maximizing patient understanding and safety.</p><p>This narrative review summarizes evidence for effective patient education on parenteral anticancer therapies. The authors propose a structured framework for oncology pharmacist-led patient education on parenteral anticancer therapies that combines pharmacotherapy knowledge and the application of patient-centered care.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 11","pages":"1202-1214"},"PeriodicalIF":1.5,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.70114","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145493725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PSAP in JACCP Case Series: Hypertension","authors":"Andrew Y. Hwang, Christina H. Sherrill","doi":"10.1002/jac5.70102","DOIUrl":"10.1002/jac5.70102","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 9","pages":"962-963"},"PeriodicalIF":1.5,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号